Plasma-Based COVID-19 Treatment Alliance Ends its Project as Trial Fails to Meet Endpoints

A Phase III clinical trial of anti-coronavirus immunoglobulin did not meet its endpoints, concluding the year-long CoVIg-19 Plasma Alliance, Takeda and CSL Behring announced.